Monoclonal antibodies in lung cancer
Monoclonal antibodies in lung cancer
复制标题
DOI：
10.1517/14712598.2012.748742
复制
发表时间：
2013-01
影响因子：
4.6
通讯作者：
Yujiong Wang;G. Deng;Xiaomin Liu;W. Cho
中科院分区：
文献类型：
--
作者：
Yujiong Wang;G. Deng;Xiaomin Liu;W. Cho
简介：肺癌是全世界癌症死亡的主要原因。由于传统癌症疗法的临床益处仍然巨大，因此迫切需要新的药物和方法来改善肺癌患者的整体临床结果。涵盖领域：本文回顾了目前对单克隆抗体（mAb）（主要是贝伐珠单抗和西妥昔单抗）肺癌靶向治疗的认识。讨论了验证贝伐珠单抗和西妥昔单抗有效性和安全性的几项关键临床试验的结果、癌症生物标志物的关系、靶向基因与基于单克隆抗体的治疗结果的多态性相关性，以及肺癌消除靶向治疗生物标志物整合方法（BATTLE）试验对肺癌个性化治疗的影响。专家意见：化疗中添加贝伐单抗或西妥昔单抗已显示出对非小细胞肺癌患者有希望的益处。然而，基于单克隆抗体的靶向治疗对肺癌患者的总体益处因人而异。因此，有必要定义可靠的预测生物标志物，以更好地识别最有可能从这些肺癌新药治疗中受益的患者。
Introduction: Lung cancer is the leading cause of cancer death worldwide. As clinical benefits to conventional cancer therapies are still formidable, there is an urgent need for novel agents and approaches to improve the overall clinical outcomes for patients with lung cancer. Areas covered: This article reviews the current understanding of targeted therapy for lung cancer with monoclonal antibodies (mAbs), mainly bevacizumab and cetuximab. The results from several key clinical trials validating the effectiveness and safety of bevacizumab and cetuximab, the relation of cancer biomarkers, the polymorphic correlation of targeted genes with the therapeutic outcome of mAb-based treatment, as well as the impact of Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial on personalised treatment of lung cancer are discussed. Expert opinion: The addition of bevacizumab or cetuximab to chemotherapy has shown promising benefits to the patients with non-small-cell lung cancer. However, the overall benefits of mAb-based targeted therapy to lung cancer patients vary among individuals. It is therefore necessary to define reliable predictive biomarkers in an effort to better identify patients who are most likely to benefit from treatment with these novel agents in lung cancer.